Last reviewed · How we verify
NCT07254468: CAN-AKI-CABG
Effect of Cardiovascular Autonomic Neuropathy on AKI and Outcomes in Isolated CABG Surgery
trial in Acute Kidney Injury (AKI) in 912 participants. Completed in 10 March 2025.
10 January 2025
Quick facts
| Lead sponsor | Akdeniz University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 912 |
| Start date | 4 November 2021 |
| Primary completion | 10 January 2025 |
| Estimated completion | 10 March 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Acute Kidney Injury (AKI) — all drugs for Acute Kidney Injury (AKI) →
- Coronary Artery Bypass Graft (CABG) — all drugs for Coronary Artery Bypass Graft (CABG) →
- Cardiovascular Autonomic Neuropathy (CAN) — all drugs for Cardiovascular Autonomic Neuropathy (CAN) →
- Postoperative Outcomes — all drugs for Postoperative Outcomes →
Sponsor
Akdeniz University
Who can join
18 and older, any sex, with Acute Kidney Injury (AKI) or Coronary Artery Bypass Graft (CABG). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to investigate the effects of Cardiovascular Autonomic Neuropathy (CAN) on Acute Kidney Injury (AKI) and clinical outcomes in patients undergoing isolated Coronary Artery Bypass Graft (CABG) surgery requiring extracorporeal circulation(ECC). Preoperative data including demographics, comorbidities, kidney function tests, hemodynamic parameters, and baseline regional cerebral oxygen saturation (rSO2) will be recorded. Intraoperative data will include hemodynamics, urine output, blood gases, cardiopulmonary bypass and aortic cross-clamp times, cardioplegia details, number of coronary anastomoses, and rSO2 changes at defined time points. Postoperatively, kidney function, neurological status, mechanical ventilation duration, inotropic drug use, transfusion requirements, complications, ICU and hospital length of stay, and mortality will be evaluated. Acute Kidney Injury will be classified according to KDIGO criteria. The primary objective is to analyze the effect of CAN on AKI. Secondary objectives include assessing the impact of CAN on other clinical outcomes and exploring the relationship between CAN and intraoperative cerebral oxygen changes. This study has been approved by the Acıbadem University and Acıbadem Healthcare Institutions Medical Research Ethics Committee (ATADEK) and will be conducted following ethical principles and good clinical practice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07254468
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Kidney Injury (AKI)
Currently open trials in the same condition.
- NCT07182422 — AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease · Phase 4 · recruiting
- NCT07101913 — Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma. · active not recruiting
Other Akdeniz University trials
Trials by the same sponsor.
- NCT07581132 — Investigation of the Effect of Structured Energy Conservation Techniques Training on COPD Patients · NA · not yet recruiting
- NCT07469345 — Bruxism, Pelvic Pain, Erectile Dysfunction, and Anxiety in Young Adult Men · enrolling by invitation
- NCT07507279 — Technology-based Hand Rehabilitation in Older People · NA · not yet recruiting
- NCT07437924 — Bruxism and Pelvic Floor Dysfunction in Young Women · enrolling by invitation
- NCT07497308 — GDF-15 and Early Outcomes After LVAD Implantation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07254468 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Akdeniz University
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07254468.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing